Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Thu, 09.03.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 9, 2023
Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a confe [ … ]
Thu, 09.03.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 9, 2023
Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a confe [ … ]
Thu, 02.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 2, 2023
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs [ … ]
Thu, 02.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 2, 2023
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs [ … ]
Mon, 09.01.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 9, 2023
MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an inves [ … ]
Thu, 05.01.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 5, 2023
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million (€ 84.9 million)
Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 8 [ … ]
Tue, 20.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 20, 2022
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons. [ … ]
Tue, 20.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 20, 2022
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons. [ … ]
Sun, 11.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 11, 2022
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination [ … ]
Sun, 11.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 11, 2022
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination [ … ]